Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease

Steven H. Itzkowitz, Daniel H. Present, Vibeke Binder, C. Richard Boland, Teresa A. Brentnall, Robynne K. Chutkan, Michael P. Cogan, Anders Ekbom, Toshihiko Ezaki, Rodger C. Haggitt, Tadakazu Hisamatsu, Per Karlén, Burton I. Korelitz, Bret A. Lashner, Lawrence Loeb, John Lennard-Jones, Robert Lofberg, Edward Vincent Loftus, Jr

Research output: Contribution to journalArticle

455 Citations (Scopus)

Abstract

The idiopathic inflammatory bowel diseases, ulcerative colitis and Crohn's colitis, are associated with an increased risk for developing colorectal cancer. To reduce colorectal cancer mortality in inflammatory bowel disease, most patients and their physicians choose to follow a program of surveillance colonoscopy in an attempt to detect early neoplastic lesions at a curable stage. Colectomy is typically reserved for patients whose biopsy findings are indicative of heightened cancer risk based on interpretation by pathologists. Despite the absence of prospective controlled clinical trials to formally evaluate the benefits, risks, and costs of this approach, enough circumstantial evidence has accrued to warrant its widespread adoption in practice. Nevertheless, no standardized guidelines have yet been set forth to guide the gastroenterologist in performing surveillance. A panel of international experts was assembled to develop consensus recommendations for the performance of surveillance. The findings are presented herein.

Original languageEnglish (US)
Pages (from-to)314-321
Number of pages8
JournalInflammatory Bowel Diseases
Volume11
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Inflammatory Bowel Diseases
Early Detection of Cancer
Colorectal Neoplasms
Colectomy
Controlled Clinical Trials
Colitis
Colonoscopy
Ulcerative Colitis
Cost-Benefit Analysis
Guidelines
Physicians
Biopsy
Mortality
Neoplasms
Gastroenterologists
Pathologists

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Consensus conference : Colorectal cancer screening and surveillance in inflammatory bowel disease. / Itzkowitz, Steven H.; Present, Daniel H.; Binder, Vibeke; Boland, C. Richard; Brentnall, Teresa A.; Chutkan, Robynne K.; Cogan, Michael P.; Ekbom, Anders; Ezaki, Toshihiko; Haggitt, Rodger C.; Hisamatsu, Tadakazu; Karlén, Per; Korelitz, Burton I.; Lashner, Bret A.; Loeb, Lawrence; Lennard-Jones, John; Lofberg, Robert; Loftus, Jr, Edward Vincent.

In: Inflammatory Bowel Diseases, Vol. 11, No. 3, 03.2005, p. 314-321.

Research output: Contribution to journalArticle

Itzkowitz, SH, Present, DH, Binder, V, Boland, CR, Brentnall, TA, Chutkan, RK, Cogan, MP, Ekbom, A, Ezaki, T, Haggitt, RC, Hisamatsu, T, Karlén, P, Korelitz, BI, Lashner, BA, Loeb, L, Lennard-Jones, J, Lofberg, R & Loftus, Jr, EV 2005, 'Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease', Inflammatory Bowel Diseases, vol. 11, no. 3, pp. 314-321. https://doi.org/10.1097/01.MIB.0000160811.76729.d5
Itzkowitz, Steven H. ; Present, Daniel H. ; Binder, Vibeke ; Boland, C. Richard ; Brentnall, Teresa A. ; Chutkan, Robynne K. ; Cogan, Michael P. ; Ekbom, Anders ; Ezaki, Toshihiko ; Haggitt, Rodger C. ; Hisamatsu, Tadakazu ; Karlén, Per ; Korelitz, Burton I. ; Lashner, Bret A. ; Loeb, Lawrence ; Lennard-Jones, John ; Lofberg, Robert ; Loftus, Jr, Edward Vincent. / Consensus conference : Colorectal cancer screening and surveillance in inflammatory bowel disease. In: Inflammatory Bowel Diseases. 2005 ; Vol. 11, No. 3. pp. 314-321.
@article{40da2cc3ea8c4087a3de59e5fd71fa88,
title = "Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease",
abstract = "The idiopathic inflammatory bowel diseases, ulcerative colitis and Crohn's colitis, are associated with an increased risk for developing colorectal cancer. To reduce colorectal cancer mortality in inflammatory bowel disease, most patients and their physicians choose to follow a program of surveillance colonoscopy in an attempt to detect early neoplastic lesions at a curable stage. Colectomy is typically reserved for patients whose biopsy findings are indicative of heightened cancer risk based on interpretation by pathologists. Despite the absence of prospective controlled clinical trials to formally evaluate the benefits, risks, and costs of this approach, enough circumstantial evidence has accrued to warrant its widespread adoption in practice. Nevertheless, no standardized guidelines have yet been set forth to guide the gastroenterologist in performing surveillance. A panel of international experts was assembled to develop consensus recommendations for the performance of surveillance. The findings are presented herein.",
author = "Itzkowitz, {Steven H.} and Present, {Daniel H.} and Vibeke Binder and Boland, {C. Richard} and Brentnall, {Teresa A.} and Chutkan, {Robynne K.} and Cogan, {Michael P.} and Anders Ekbom and Toshihiko Ezaki and Haggitt, {Rodger C.} and Tadakazu Hisamatsu and Per Karl{\'e}n and Korelitz, {Burton I.} and Lashner, {Bret A.} and Lawrence Loeb and John Lennard-Jones and Robert Lofberg and {Loftus, Jr}, {Edward Vincent}",
year = "2005",
month = "3",
doi = "10.1097/01.MIB.0000160811.76729.d5",
language = "English (US)",
volume = "11",
pages = "314--321",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Consensus conference

T2 - Colorectal cancer screening and surveillance in inflammatory bowel disease

AU - Itzkowitz, Steven H.

AU - Present, Daniel H.

AU - Binder, Vibeke

AU - Boland, C. Richard

AU - Brentnall, Teresa A.

AU - Chutkan, Robynne K.

AU - Cogan, Michael P.

AU - Ekbom, Anders

AU - Ezaki, Toshihiko

AU - Haggitt, Rodger C.

AU - Hisamatsu, Tadakazu

AU - Karlén, Per

AU - Korelitz, Burton I.

AU - Lashner, Bret A.

AU - Loeb, Lawrence

AU - Lennard-Jones, John

AU - Lofberg, Robert

AU - Loftus, Jr, Edward Vincent

PY - 2005/3

Y1 - 2005/3

N2 - The idiopathic inflammatory bowel diseases, ulcerative colitis and Crohn's colitis, are associated with an increased risk for developing colorectal cancer. To reduce colorectal cancer mortality in inflammatory bowel disease, most patients and their physicians choose to follow a program of surveillance colonoscopy in an attempt to detect early neoplastic lesions at a curable stage. Colectomy is typically reserved for patients whose biopsy findings are indicative of heightened cancer risk based on interpretation by pathologists. Despite the absence of prospective controlled clinical trials to formally evaluate the benefits, risks, and costs of this approach, enough circumstantial evidence has accrued to warrant its widespread adoption in practice. Nevertheless, no standardized guidelines have yet been set forth to guide the gastroenterologist in performing surveillance. A panel of international experts was assembled to develop consensus recommendations for the performance of surveillance. The findings are presented herein.

AB - The idiopathic inflammatory bowel diseases, ulcerative colitis and Crohn's colitis, are associated with an increased risk for developing colorectal cancer. To reduce colorectal cancer mortality in inflammatory bowel disease, most patients and their physicians choose to follow a program of surveillance colonoscopy in an attempt to detect early neoplastic lesions at a curable stage. Colectomy is typically reserved for patients whose biopsy findings are indicative of heightened cancer risk based on interpretation by pathologists. Despite the absence of prospective controlled clinical trials to formally evaluate the benefits, risks, and costs of this approach, enough circumstantial evidence has accrued to warrant its widespread adoption in practice. Nevertheless, no standardized guidelines have yet been set forth to guide the gastroenterologist in performing surveillance. A panel of international experts was assembled to develop consensus recommendations for the performance of surveillance. The findings are presented herein.

UR - http://www.scopus.com/inward/record.url?scp=20144388645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144388645&partnerID=8YFLogxK

U2 - 10.1097/01.MIB.0000160811.76729.d5

DO - 10.1097/01.MIB.0000160811.76729.d5

M3 - Article

C2 - 15735438

AN - SCOPUS:20144388645

VL - 11

SP - 314

EP - 321

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 3

ER -